Literature DB >> 22561520

Exome sequencing of liver fluke-associated cholangiocarcinoma.

Choon Kiat Ong1, Chutima Subimerb, Chawalit Pairojkul, Sopit Wongkham, Ioana Cutcutache, Willie Yu, John R McPherson, George E Allen, Cedric Chuan Young Ng, Bernice Huimin Wong, Swe Swe Myint, Vikneswari Rajasegaran, Hong Lee Heng, Anna Gan, Zhi Jiang Zang, Yingting Wu, Jeanie Wu, Ming Hui Lee, DaChuan Huang, Pauline Ong, Waraporn Chan-on, Yun Cao, Chao-Nan Qian, Kiat Hon Lim, Aikseng Ooi, Karl Dykema, Kyle Furge, Veerapol Kukongviriyapan, Banchob Sripa, Chaisiri Wongkham, Puangrat Yongvanit, P Andrew Futreal, Vajarabhongsa Bhudhisawasdi, Steve Rozen, Patrick Tan, Bin Tean Teh.   

Abstract

Opisthorchis viverrini-related cholangiocarcinoma (CCA), a fatal bile duct cancer, is a major public health concern in areas endemic for this parasite. We report here whole-exome sequencing of eight O. viverrini-related tumors and matched normal tissue. We identified and validated 206 somatic mutations in 187 genes using Sanger sequencing and selected 15 genes for mutation prevalence screening in an additional 46 individuals with CCA (cases). In addition to the known cancer-related genes TP53 (mutated in 44.4% of cases), KRAS (16.7%) and SMAD4 (16.7%), we identified somatic mutations in 10 newly implicated genes in 14.8-3.7% of cases. These included inactivating mutations in MLL3 (in 14.8% of cases), ROBO2 (9.3%), RNF43 (9.3%) and PEG3 (5.6%), and activating mutations in the GNAS oncogene (9.3%). These genes have functions that can be broadly grouped into three biological classes: (i) deactivation of histone modifiers, (ii) activation of G protein signaling and (iii) loss of genome stability. This study provides insight into the mutational landscape contributing to O. viverrini-related CCA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22561520     DOI: 10.1038/ng.2273

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  30 in total

1.  Signal transduction in neuronal migration: roles of GTPase activating proteins and the small GTPase Cdc42 in the Slit-Robo pathway.

Authors:  K Wong; X R Ren; Y Z Huang; Y Xie; G Liu; H Saito; H Tang; L Wen; S M Brady-Kalnay; L Mei; J Y Wu; W C Xiong; Y Rao
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

2.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

3.  Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States.

Authors:  Luciana McLean; Tushar Patel
Journal:  Liver Int       Date:  2006-11       Impact factor: 5.828

4.  K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China.

Authors:  Asif Rashid; Takashi Ueki; Yu-Tang Gao; Patrick Scott Houlihan; Charita Wallace; Bing-Sheng Wang; Ming-Chang Shen; Jie Deng; Ann W Hsing
Journal:  Clin Cancer Res       Date:  2002-10       Impact factor: 12.531

5.  Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice.

Authors:  Xiaoling Xu; Shogo Kobayashi; Wenhui Qiao; Cuiling Li; Cuiying Xiao; Svetlana Radaeva; Bangyan Stiles; Rui-Hong Wang; Nobuya Ohara; Tadashi Yoshino; Derek LeRoith; Michael S Torbenson; Gregory J Gores; Hong Wu; Bin Gao; Chu-Xia Deng
Journal:  J Clin Invest       Date:  2006-06-08       Impact factor: 14.808

6.  Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.

Authors:  Jian Wu; Hanno Matthaei; Anirban Maitra; Marco Dal Molin; Laura D Wood; James R Eshleman; Michael Goggins; Marcia I Canto; Richard D Schulick; Barish H Edil; Christopher L Wolfgang; Alison P Klein; Luis A Diaz; Peter J Allen; C Max Schmidt; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Sci Transl Med       Date:  2011-07-20       Impact factor: 17.956

7.  Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells.

Authors:  K Aoki; M Aoki; M Sugai; N Harada; H Miyoshi; T Tsukamoto; T Mizoshita; M Tatematsu; H Seno; T Chiba; M Oshima; C-L Hsieh; M M Taketo
Journal:  Oncogene       Date:  2006-12-11       Impact factor: 9.867

8.  TumorBoost: normalization of allele-specific tumor copy numbers from a single pair of tumor-normal genotyping microarrays.

Authors:  Henrik Bengtsson; Pierre Neuvial; Terence P Speed
Journal:  BMC Bioinformatics       Date:  2010-05-12       Impact factor: 3.169

9.  Genome-wide association study of pancreatic cancer in Japanese population.

Authors:  Siew-Kee Low; Aya Kuchiba; Hitoshi Zembutsu; Akira Saito; Atsushi Takahashi; Michiaki Kubo; Yataro Daigo; Naoyuki Kamatani; Suenori Chiku; Hirohiko Totsuka; Sumiko Ohnami; Hiroshi Hirose; Kazuaki Shimada; Takuji Okusaka; Teruhiko Yoshida; Yusuke Nakamura; Hiromi Sakamoto
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

10.  A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6.

Authors:  Henrik Bengtsson; Pratyaksha Wirapati; Terence P Speed
Journal:  Bioinformatics       Date:  2009-06-17       Impact factor: 6.937

View more
  205 in total

Review 1.  Cholangiocarcinoma: molecular pathways and therapeutic opportunities.

Authors:  Sumera Rizvi; Mitesh J Borad; Tushar Patel; Gregory J Gores
Journal:  Semin Liver Dis       Date:  2014-11-04       Impact factor: 6.115

2.  Cancer: Net closes in on genetics of liver fluke-associated cholangiocarcinoma.

Authors:  Natalie J Wood
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

3.  Building a staircase to precision medicine for biliary tract cancer.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Nat Genet       Date:  2015-09       Impact factor: 38.330

Review 4.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

5.  Genetic landscape of esophageal squamous cell carcinoma.

Authors:  Yi-Bo Gao; Zhao-Li Chen; Jia-Gen Li; Xue-Da Hu; Xue-Jiao Shi; Zeng-Miao Sun; Fan Zhang; Zi-Ran Zhao; Zi-Tong Li; Zi-Yuan Liu; Yu-Da Zhao; Jian Sun; Cheng-Cheng Zhou; Ran Yao; Su-Ya Wang; Pan Wang; Nan Sun; Bai-Hua Zhang; Jing-Si Dong; Yue Yu; Mei Luo; Xiao-Li Feng; Su-Sheng Shi; Fang Zhou; Feng-Wei Tan; Bin Qiu; Ning Li; Kang Shao; Li-Jian Zhang; Lan-Jun Zhang; Qi Xue; Shu-Geng Gao; Jie He
Journal:  Nat Genet       Date:  2014-08-24       Impact factor: 38.330

Review 6.  Cholangiocarcinoma.

Authors:  Nataliya Razumilava; Gregory J Gores
Journal:  Lancet       Date:  2014-02-26       Impact factor: 79.321

7.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

Review 8.  Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.

Authors:  Mitesh J Borad; Gregory J Gores; Lewis R Roberts
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

Review 9.  The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer.

Authors:  Hwajeong Lee; Jeffrey S Ross
Journal:  Therap Adv Gastroenterol       Date:  2017-03-28       Impact factor: 4.409

10.  Role of 5-hydroxymethylcytosine level in diagnosis and prognosis prediction of intrahepatic cholangiocarcinoma.

Authors:  Zhao-Ru Dong; Chi Zhang; Jia-Bin Cai; Peng-Fei Zhang; Guo-Ming Shi; Dong-Mei Gao; Hui-Chuan Sun; Shuang-Jian Qiu; Jian Zhou; Ai-Wu Ke; Jia Fan
Journal:  Tumour Biol       Date:  2014-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.